Abstract
Life expectancy has impressively increased over the past century and the US population over 65 years is rapidly growing, especially those over 80 years. In fact, persons older than 80 years have increased by more than 250% between the years 1960 and 2000, and it is expected that the population aged >75 years will triple by the year 2030. With the increase of the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients needs special attention because older patients usually suffered of several co-morbidities and their management represents a challenge for physicians. In fact, older patients treated for lymphoma may not tolerate the high-dose therapies used in younger patients and have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities. The widespread use of a comprehensive geriatric assessment tool might overcome the difficulty to run prospective clinical trial in elderly patients with lymphoma.
Keywords: Elderly patients, lymphoma, comprehensive geriatric assessment, therapy related toxicity.
Anti-Cancer Agents in Medicinal Chemistry
Title:Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas
Volume: 13 Issue: 9
Author(s): Rosanna Ciancia, Umberto Tirelli, Josep-Maria Ribera and Michele Spina
Affiliation:
Keywords: Elderly patients, lymphoma, comprehensive geriatric assessment, therapy related toxicity.
Abstract: Life expectancy has impressively increased over the past century and the US population over 65 years is rapidly growing, especially those over 80 years. In fact, persons older than 80 years have increased by more than 250% between the years 1960 and 2000, and it is expected that the population aged >75 years will triple by the year 2030. With the increase of the geriatric population, there is a need for the development and validation of treatment strategies for NHL for these patients. Therapy in elderly patients needs special attention because older patients usually suffered of several co-morbidities and their management represents a challenge for physicians. In fact, older patients treated for lymphoma may not tolerate the high-dose therapies used in younger patients and have increased risk of therapy-related toxicity as a result of age-related physiological changes and frequent co-morbidities. The widespread use of a comprehensive geriatric assessment tool might overcome the difficulty to run prospective clinical trial in elderly patients with lymphoma.
Export Options
About this article
Cite this article as:
Ciancia Rosanna, Tirelli Umberto, Ribera Josep-Maria and Spina Michele, Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (9) . https://dx.doi.org/10.2174/18715206113136660363
DOI https://dx.doi.org/10.2174/18715206113136660363 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Current Pharmaceutical Design Targeting Glycogen Synthase Kinase-3 in the CNS: Implications for the Development of New Treatments for Mood Disorders
Current Drug Targets Plasticity and Therapeutic Potential of Mesenchymal Stem Cells in the Nervous System
Current Pharmaceutical Design Self-aggregated Nanoparticles of Cholesterol-modified Pullulan Conjugate as a Novel Carrier of Mitoxantronep
Current Nanoscience Gold and Silver Nanoparticles for Applications in Theranostics
Current Topics in Medicinal Chemistry Chromosomal Translocations as Biomarkers in Leukemia Diagnosis and Pharmacogenomics
Recent Patents on Biomarkers Direct Gene Expression Analysis
Current Pharmaceutical Biotechnology Ginkgolic Acids Confer Potential Anticancer Effects by Targeting Pro- Inflammatory and Oncogenic Signaling Molecules
Current Molecular Pharmacology Editorial (Thematic Issue: Advances in Drug Discovery for the Treatment of Cancer: Many Approaches, One Goal)
Current Topics in Medicinal Chemistry SUMOylation Regulation of Retina Development and Functions
Current Molecular Medicine Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Radiopharmaceuticals for Oncology Drug Development: A Pharmaceutical Industry Perspective
Current Pharmaceutical Design OX40:OX40L Axis: Emerging Targets for Immunotherapy of Human Disease
Current Immunology Reviews (Discontinued) Protein Modification by β-N-Acetyl Glucosamine (O-GlcNAc) in Insulin Signaling and Insulin Resistance
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Computer-Aided Drug Design of Bioactive Natural Products
Current Topics in Medicinal Chemistry Latest Advancements on Serotonin and Dopamine Transporters in Lymphocytes
Mini-Reviews in Medicinal Chemistry Development of Vascular Endothelial Growth Factor Receptor (VEGFR) Kinase Inhibitors as Anti-Angiogenic Agents in Cancer Therapy
Current Medicinal Chemistry Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Current Molecular Pharmacology Development of Arene Ruthenium Antitumor Complexes
Mini-Reviews in Medicinal Chemistry ABC Transporters in the Development of Multidrug Resistance in Cancer Therapy
Current Pharmaceutical Design